OncoImmunology (Feb 2019)

CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers

  • Yu Tian,
  • Yi Sun,
  • Fan Gao,
  • Michelle R. Koenig,
  • Alexander Sunderland,
  • Yuki Fujiwara,
  • Robert J. Torphy,
  • Lieping Chen,
  • Barish H. Edil,
  • Richard D. Schulick,
  • Yuwen Zhu

DOI
https://doi.org/10.1080/2162402X.2018.1538440
Journal volume & issue
Vol. 8, no. 2

Abstract

Read online

The CD28H/B7-H5 pathway is a newly identified pathway of the B7 family. In human peripheral blood, the receptor CD28H is preferentially expressed on naïve T cells and repetitive stimulation of T cells leads to the loss of CD28H expression. Here we examined the expression of the CD28H/B7-H5 pathway in human peripheral tissues, as well as in human cancers. We found that CD28H is preferentially expressed on T cells with tissue-resident phenotypes (TRM). Supporting that, stimulation via IL-15 and TGF-β, presumably major cytokines essential for TRM cell homeostasis, sustains CD28H expression on T cells. The ligand B7-H5 is constitutively expressed on normal epithelium of human oral-gastrointestinal tracts. In human cancers, CD28H is preferentially present on tumor infiltrating lymphocytes (TILs) with TRM features and identifies a TRM subset with less cytotoxicity. Taken together, our studies suggest that the CD28H/B7-H5 pathway involves the interactions between TRM cells and epithelium, and could be important for human TRM homeostasis and function.

Keywords